Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives
- 3.3k Downloads
The expansion of the biologics pipeline depends on the identification of candidate proteins for clinical trials. Speed is one of the critical issues, and the rapid production of high quality, research-grade material for preclinical studies by transient gene expression (TGE) is addressing this factor in an impressive way: following DNA transfection, the production phase for TGE is usually 2–10 days. Recombinant proteins (r-proteins) produced by TGE can therefore enter the drug development and screening process in a very short time––weeks. With “classical” approaches to protein expression from mammalian cells, it takes months to establish a productive host cell line. This article summarizes efforts in industry and academia to use TGE to produce tens to hundreds of milligrams of r-proteins for either fundamental research or preclinical studies.
KeywordsMammalian cells Non-viral gene delivery Recombinant protein Transient gene expression
The authors wish to thank Matthieu Stettler, Sarah Wuhlfard and Markus Hildinger for sharing unpublished results. This work was partly supported by the swiss KTI/CTI (Science to Market Fund). We thank A. Kühner AG for providing cell culture incubator shakers.
- Kost TA, Klein JL, Condreay JP (2000) Application of Recombinant Baculoviruses in Biopharmaceutical Research. In: Al-Rubeai M, Fussenegger M (eds) Cell engineering, Kluwer Academic PublishersGoogle Scholar
- Muller N (2005) Transient gene expression for rapid protein production: studies & optimizations under serum-free conditions. Dissertation, Ècole Polytechnique Fédérale de LausanneGoogle Scholar
- Stadler J, Lemmens R, Nyhammar T (2004) Plasmid DNA purification. J Gene Med 6 Supply 1:S54–S66Google Scholar